Selected research
Market Structure
Global Alternative to Antibiotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Alternative to Antibiotics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Alternative to Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Alternative to Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Alternative to Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Alternative to Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Alternative to Antibiotics include DSM, BioGaia, Bioriginal, Biosearch Life, China-Biotics, Chr. Hansen, Danone, DuPont(Danisco) and Ganeden, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Alternative to Antibiotics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Alternative to Antibiotics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Alternative to Antibiotics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alternative to Antibiotics market size, projected growth trends, production technologies, key applications, and end-use industries.
Alternative to Antibiotics Segment by Company
DSM
BioGaia
Bioriginal
Biosearch Life
China-Biotics
Chr. Hansen
Danone
DuPont(Danisco)
Ganeden
Glory Biotech
Greentech
Lallemand
Morinaga Milk Industry
Novozymes
Probi
Sabinsa
Synbiotech
UAS Laboratories
Valio
Yakult
Nestle
Alternative to Antibiotics Segment by Type
Antimicrobial Proteins
Bacteriophages
Probiotics
Other
Alternative to Antibiotics Segment by Application
Drugs
Food & Beverage
Dietary Supplements
Alternative to Antibiotics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alternative to Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alternative to Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alternative to Antibiotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Alternative to Antibiotics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alternative to Antibiotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Alternative to Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Alternative to Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Alternative to Antibiotics Industry Trends
Table 2. Alternative to Antibiotics Industry Drivers
Table 3. Alternative to Antibiotics Industry Opportunities and Challenges
Table 4. Alternative to Antibiotics Industry Restraints
Table 5. Global Alternative to Antibiotics Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Alternative to Antibiotics Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Alternative to Antibiotics Sales by Manufacturers (K Units) & (2021-2026)
Table 8. Global Alternative to Antibiotics Sales Market Share by Manufacturers
Table 9. Global Alternative to Antibiotics Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Alternative to Antibiotics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Alternative to Antibiotics Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Alternative to Antibiotics Manufacturers, Product Type & Application
Table 13. Global Alternative to Antibiotics Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Alternative to Antibiotics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Antimicrobial Proteins
Table 17. Major Manufacturers of Bacteriophages
Table 18. Major Manufacturers of Probiotics
Table 19. Major Manufacturers of Other
Table 20. Global Alternative to Antibiotics Sales by Type 2021 VS 2025 VS 2032 (K Units)
Table 21. Global Alternative to Antibiotics Sales by Type (2021-2026) & (K Units)
Table 22. Global Alternative to Antibiotics Sales by Type (2027-2032) & (K Units)
Table 23. Global Alternative to Antibiotics Sales Market Share by Type (2021-2026)
Table 24. Global Alternative to Antibiotics Sales Market Share by Type (2027-2032)
Table 25. Global Alternative to Antibiotics Revenue by Type 2021 VS 2025 VS 2032 (K Units)
Table 26. Global Alternative to Antibiotics Revenue by Type (2021-2026) & (K Units)
Table 27. Global Alternative to Antibiotics Revenue by Type (2027-2032) & (K Units)
Table 28. Global Alternative to Antibiotics Revenue Market Share by Type (2021-2026)
Table 29. Global Alternative to Antibiotics Revenue Market Share by Type (2027-2032)
Table 30. Major Manufacturers of Drugs
Table 31. Major Manufacturers of Food & Beverage
Table 32. Major Manufacturers of Dietary Supplements
Table 33. Global Alternative to Antibiotics Sales by Application 2021 VS 2025 VS 2032 (K Units)
Table 34. Global Alternative to Antibiotics Sales by Application (2021-2026) & (K Units)
Table 35. Global Alternative to Antibiotics Sales by Application (2027-2032) & (K Units)
Table 36. Global Alternative to Antibiotics Sales Market Share by Application (2021-2026)
Table 37. Global Alternative to Antibiotics Sales Market Share by Application (2027-2032)
Table 38. Global Alternative to Antibiotics Revenue by Application 2021 VS 2025 VS 2032 (K Units)
Table 39. Global Alternative to Antibiotics Revenue by Application (2021-2026) & (K Units)
Table 40. Global Alternative to Antibiotics Revenue by Application (2027-2032) & (K Units)
Table 41. Global Alternative to Antibiotics Revenue Market Share by Application (2021-2026)
Table 42. Global Alternative to Antibiotics Revenue Market Share by Application (2027-2032)
Table 43. Global Alternative to Antibiotics Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 44. Global Alternative to Antibiotics Sales by Region (2021-2026) & (K Units)
Table 45. Global Alternative to Antibiotics Sales Market Share by Region (2021-2026)
Table 46. Global Alternative to Antibiotics Sales Forecasted by Region (2027-2032) & (K Units)
Table 47. Global Alternative to Antibiotics Sales Forecasted Market Share by Region (2027-2032)
Table 48. North America Alternative to Antibiotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 49. North America Alternative to Antibiotics Sales by Country (2021-2026) & (K Units)
Table 50. North America Alternative to Antibiotics Sales by Country (2027-2032) & (K Units)
Table 51. Europe Alternative to Antibiotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 52. Europe Alternative to Antibiotics Sales by Country (2021-2026) & (K Units)
Table 53. Europe Alternative to Antibiotics Sales by Country (2027-2032) & (K Units)
Table 54. Asia Pacific Alternative to Antibiotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 55. Asia Pacific Alternative to Antibiotics Sales by Country (2021-2026) & (K Units)
Table 56. Asia Pacific Alternative to Antibiotics Sales by Country (2027-2032) & (K Units)
Table 57. South America, Middle East and Africa Alternative to Antibiotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 58. South America, Middle East and Africa Alternative to Antibiotics Sales by Country (2021-2026) & (K Units)
Table 59. South America, Middle East and Africa Alternative to Antibiotics Sales by Country (2027-2032) & (K Units)
Table 60. Global Alternative to Antibiotics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 61. Global Alternative to Antibiotics Revenue by Region (2021-2026) & (US$ Million)
Table 62. Global Alternative to Antibiotics Revenue by Region (2027-2032) & (US$ Million)
Table 63. Global Alternative to Antibiotics Revenue Market Share by Region (2021-2026)
Table 64. Global Alternative to Antibiotics Revenue Market Share by Region (2027-2032)
Table 65. DSM Company Information
Table 66. DSM Business Overview
Table 67. DSM Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. DSM Alternative to Antibiotics Product Portfolio
Table 69. DSM Recent Development
Table 70. BioGaia Company Information
Table 71. BioGaia Business Overview
Table 72. BioGaia Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. BioGaia Alternative to Antibiotics Product Portfolio
Table 74. BioGaia Recent Development
Table 75. Bioriginal Company Information
Table 76. Bioriginal Business Overview
Table 77. Bioriginal Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. Bioriginal Alternative to Antibiotics Product Portfolio
Table 79. Bioriginal Recent Development
Table 80. Biosearch Life Company Information
Table 81. Biosearch Life Business Overview
Table 82. Biosearch Life Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. Biosearch Life Alternative to Antibiotics Product Portfolio
Table 84. Biosearch Life Recent Development
Table 85. China-Biotics Company Information
Table 86. China-Biotics Business Overview
Table 87. China-Biotics Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. China-Biotics Alternative to Antibiotics Product Portfolio
Table 89. China-Biotics Recent Development
Table 90. Chr. Hansen Company Information
Table 91. Chr. Hansen Business Overview
Table 92. Chr. Hansen Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. Chr. Hansen Alternative to Antibiotics Product Portfolio
Table 94. Chr. Hansen Recent Development
Table 95. Danone Company Information
Table 96. Danone Business Overview
Table 97. Danone Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 98. Danone Alternative to Antibiotics Product Portfolio
Table 99. Danone Recent Development
Table 100. DuPont(Danisco) Company Information
Table 101. DuPont(Danisco) Business Overview
Table 102. DuPont(Danisco) Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 103. DuPont(Danisco) Alternative to Antibiotics Product Portfolio
Table 104. DuPont(Danisco) Recent Development
Table 105. Ganeden Company Information
Table 106. Ganeden Business Overview
Table 107. Ganeden Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 108. Ganeden Alternative to Antibiotics Product Portfolio
Table 109. Ganeden Recent Development
Table 110. Glory Biotech Company Information
Table 111. Glory Biotech Business Overview
Table 112. Glory Biotech Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 113. Glory Biotech Alternative to Antibiotics Product Portfolio
Table 114. Glory Biotech Recent Development
Table 115. Greentech Company Information
Table 116. Greentech Business Overview
Table 117. Greentech Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 118. Greentech Alternative to Antibiotics Product Portfolio
Table 119. Greentech Recent Development
Table 120. Lallemand Company Information
Table 121. Lallemand Business Overview
Table 122. Lallemand Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 123. Lallemand Alternative to Antibiotics Product Portfolio
Table 124. Lallemand Recent Development
Table 125. Morinaga Milk Industry Company Information
Table 126. Morinaga Milk Industry Business Overview
Table 127. Morinaga Milk Industry Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 128. Morinaga Milk Industry Alternative to Antibiotics Product Portfolio
Table 129. Morinaga Milk Industry Recent Development
Table 130. Novozymes Company Information
Table 131. Novozymes Business Overview
Table 132. Novozymes Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 133. Novozymes Alternative to Antibiotics Product Portfolio
Table 134. Novozymes Recent Development
Table 135. Probi Company Information
Table 136. Probi Business Overview
Table 137. Probi Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 138. Probi Alternative to Antibiotics Product Portfolio
Table 139. Probi Recent Development
Table 140. Sabinsa Company Information
Table 141. Sabinsa Business Overview
Table 142. Sabinsa Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 143. Sabinsa Alternative to Antibiotics Product Portfolio
Table 144. Sabinsa Recent Development
Table 145. Synbiotech Company Information
Table 146. Synbiotech Business Overview
Table 147. Synbiotech Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 148. Synbiotech Alternative to Antibiotics Product Portfolio
Table 149. Synbiotech Recent Development
Table 150. UAS Laboratories Company Information
Table 151. UAS Laboratories Business Overview
Table 152. UAS Laboratories Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 153. UAS Laboratories Alternative to Antibiotics Product Portfolio
Table 154. UAS Laboratories Recent Development
Table 155. Valio Company Information
Table 156. Valio Business Overview
Table 157. Valio Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 158. Valio Alternative to Antibiotics Product Portfolio
Table 159. Valio Recent Development
Table 160. Yakult Company Information
Table 161. Yakult Business Overview
Table 162. Yakult Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 163. Yakult Alternative to Antibiotics Product Portfolio
Table 164. Yakult Recent Development
Table 165. Nestle Company Information
Table 166. Nestle Business Overview
Table 167. Nestle Alternative to Antibiotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 168. Nestle Alternative to Antibiotics Product Portfolio
Table 169. Nestle Recent Development
Table 170. Key Raw Materials
Table 171. Raw Materials Key Suppliers
Table 172. Alternative to Antibiotics Distributors List
Table 173. Alternative to Antibiotics Customers List
Table 174. Research Programs/Design for This Report
Table 175. Authors List of This Report
Table 176. Secondary Sources
Table 177. Primary Sources
List of Figures
Figure 1. Alternative to Antibiotics Product Image
Figure 2. Global Alternative to Antibiotics Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Alternative to Antibiotics Market Size (2021-2032) & (US$ Million)
Figure 4. Global Alternative to Antibiotics Sales (2021-2032) & (K Units)
Figure 5. Global Alternative to Antibiotics Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Alternative to Antibiotics Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Antimicrobial Proteins Image
Figure 9. Bacteriophages Image
Figure 10. Probiotics Image
Figure 11. Other Image
Figure 12. Global Alternative to Antibiotics Sales by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 13. Global Alternative to Antibiotics Sales Market Share 2021 VS 2025 VS 2032
Figure 14. Global Alternative to Antibiotics Sales Market Share by Type (2021-2032)
Figure 15. Global Alternative to Antibiotics Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 16. Global Alternative to Antibiotics Revenue Market Share 2021 VS 2025 VS 2032
Figure 17. Global Alternative to Antibiotics Revenue Market Share by Type (2021-2032)
Figure 18. Drugs Image
Figure 19. Food & Beverage Image
Figure 20. Dietary Supplements Image
Figure 21. Global Alternative to Antibiotics Sales by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 22. Global Alternative to Antibiotics Sales Market Share 2021 VS 2025 VS 2032
Figure 23. Global Alternative to Antibiotics Sales Market Share by Application (2021-2032)
Figure 24. Global Alternative to Antibiotics Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 25. Global Alternative to Antibiotics Revenue Market Share 2021 VS 2025 VS 2032
Figure 26. Global Alternative to Antibiotics Revenue Market Share by Application (2021-2032)
Figure 27. North America Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 28. North America Alternative to Antibiotics Sales Market Share by Country (2021-2032)
Figure 29. U.S. Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 30. Canada Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 31. Mexico Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 32. Europe Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 33. Europe Alternative to Antibiotics Sales Market Share by Country (2021-2032)
Figure 34. Germany Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 35. France Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 36. U.K. Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 37. Italy Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 38. Netherlands Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 39. Asia Pacific Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 40. Asia Pacific Alternative to Antibiotics Sales Market Share by Country (2021-2032)
Figure 41. China Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 42. Japan Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 43. South Korea Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 44. Southeast Asia Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 45. India Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 46. Australia Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 47. South America, Middle East and Africa Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 48. South America, Middle East and Africa Alternative to Antibiotics Sales Market Share by Country (2021-2032)
Figure 49. Brazil Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 50. South Africa Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 51. Saudi Arabia Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 52. Turkey Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 53. Argentina Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 54. UAE Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 55. Egypt Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 56. Chile Alternative to Antibiotics Sales and Growth Rate (2021-2032) & (K Units)
Figure 57. Global Alternative to Antibiotics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 58. Global Alternative to Antibiotics Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 59. North America Alternative to Antibiotics Revenue (2021-2032) & (US$ Million)
Figure 60. North America Alternative to Antibiotics Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 61. Europe Alternative to Antibiotics Revenue (2021-2032) & (US$ Million)
Figure 62. Europe Alternative to Antibiotics Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 63. Asia-Pacific Alternative to Antibiotics Revenue (2021-2032) & (US$ Million)
Figure 64. Asia-Pacific Alternative to Antibiotics Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 65. South America, Middle East and Africa Alternative to Antibiotics Revenue (2021-2032) & (US$ Million)
Figure 66. South America, Middle East and Africa Alternative to Antibiotics Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 67. Alternative to Antibiotics Value Chain
Figure 68. Manufacturing Cost Structure
Figure 69. Alternative to Antibiotics Production Mode & Process
Figure 70. Direct Comparison with Distribution Share
Figure 71. Distributors Profiles
Figure 72. Years Considered
Figure 73. Research Process
Figure 74. Key Executives Interviewed
Scope & coverage.
Types
- Antimicrobial Proteins
- Bacteriophages
- Probiotics
- Other
Applications
- Drugs
- Food & Beverage
- Dietary Supplements
Companies covered
- DSM
- BioGaia
- Bioriginal
- Biosearch Life
- China-Biotics
- Chr. Hansen
- Danone
- DuPont(Danisco)
- Ganeden
- Glory Biotech
- Greentech
- Lallemand
- Morinaga Milk Industry
- Novozymes
- Probi
- Sabinsa
- Synbiotech
- UAS Laboratories
- Valio
- Yakult
- Nestle
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Alternative to Antibiotics Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Alternative to Antibiotics Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Alternative to Antibiotics Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Alternative to Antibiotics Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Alternative to Antibiotics Market Dynamics
- 2.1 Alternative to Antibiotics Industry Trends
- 2.2 Alternative to Antibiotics Industry Drivers
- 2.3 Alternative to Antibiotics Industry Opportunities and Challenges
- 2.4 Alternative to Antibiotics Industry Restraints
3 Alternative to Antibiotics Market by Manufacturers
- 3.1 Global Alternative to Antibiotics Revenue by Manufacturers (2021-2026)
- 3.2 Global Alternative to Antibiotics Sales by Manufacturers (2021-2026)
- 3.3 Global Alternative to Antibiotics Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Alternative to Antibiotics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Alternative to Antibiotics Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Alternative to Antibiotics Manufacturers, Product Type & Application
- 3.7 Global Alternative to Antibiotics Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Alternative to Antibiotics Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Alternative to Antibiotics Players Market Share by Revenue in 2025
- 3.8.3 2025 Alternative to Antibiotics Tier 1, Tier 2, and Tier 3
4 Alternative to Antibiotics Market by Type
- 4.1 Alternative to Antibiotics Type Introduction
- 4.1.1 Antimicrobial Proteins
- 4.1.2 Bacteriophages
- 4.1.3 Probiotics
- 4.1.4 Other
- 4.2 Global Alternative to Antibiotics Sales by Type
- 4.2.1 Global Alternative to Antibiotics Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Alternative to Antibiotics Sales by Type (2021-2032)
- 4.2.3 Global Alternative to Antibiotics Sales Market Share by Type (2021-2032)
- 4.3 Global Alternative to Antibiotics Revenue by Type
- 4.3.1 Global Alternative to Antibiotics Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Alternative to Antibiotics Revenue by Type (2021-2032)
- 4.3.3 Global Alternative to Antibiotics Revenue Market Share by Type (2021-2032)
5 Alternative to Antibiotics Market by Application
- 5.1 Alternative to Antibiotics Application Introduction
- 5.1.1 Drugs
- 5.1.2 Food & Beverage
- 5.1.3 Dietary Supplements
- 5.2 Global Alternative to Antibiotics Sales by Application
- 5.2.1 Global Alternative to Antibiotics Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Alternative to Antibiotics Sales by Application (2021-2032)
- 5.2.3 Global Alternative to Antibiotics Sales Market Share by Application (2021-2032)
- 5.3 Global Alternative to Antibiotics Revenue by Application
- 5.3.1 Global Alternative to Antibiotics Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Alternative to Antibiotics Revenue by Application (2021-2032)
- 5.3.3 Global Alternative to Antibiotics Revenue Market Share by Application (2021-2032)
6 Global Alternative to Antibiotics Sales by Region
- 6.1 Global Alternative to Antibiotics Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Alternative to Antibiotics Sales by Region (2021-2032)
- 6.2.1 Global Alternative to Antibiotics Sales by Region (2021-2026)
- 6.2.2 Global Alternative to Antibiotics Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Alternative to Antibiotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Alternative to Antibiotics Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Alternative to Antibiotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Alternative to Antibiotics Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Alternative to Antibiotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Alternative to Antibiotics Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Alternative to Antibiotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Alternative to Antibiotics Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Alternative to Antibiotics Revenue by Region
- 7.1 Global Alternative to Antibiotics Revenue by Region
- 7.1.1 Global Alternative to Antibiotics Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Alternative to Antibiotics Revenue by Region (2021-2026)
- 7.1.3 Global Alternative to Antibiotics Revenue by Region (2027-2032)
- 7.1.4 Global Alternative to Antibiotics Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Alternative to Antibiotics Revenue (2021-2032)
- 7.2.2 North America Alternative to Antibiotics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Alternative to Antibiotics Revenue (2021-2032)
- 7.3.2 Europe Alternative to Antibiotics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Alternative to Antibiotics Revenue (2021-2032)
- 7.4.2 Asia-Pacific Alternative to Antibiotics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Alternative to Antibiotics Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Alternative to Antibiotics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 DSM
- 8.1.1 DSM Company Information
- 8.1.2 DSM Business Overview
- 8.1.3 DSM Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 DSM Alternative to Antibiotics Product Portfolio
- 8.1.5 DSM Recent Developments
- 8.2 BioGaia
- 8.2.1 BioGaia Company Information
- 8.2.2 BioGaia Business Overview
- 8.2.3 BioGaia Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 BioGaia Alternative to Antibiotics Product Portfolio
- 8.2.5 BioGaia Recent Developments
- 8.3 Bioriginal
- 8.3.1 Bioriginal Company Information
- 8.3.2 Bioriginal Business Overview
- 8.3.3 Bioriginal Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Bioriginal Alternative to Antibiotics Product Portfolio
- 8.3.5 Bioriginal Recent Developments
- 8.4 Biosearch Life
- 8.4.1 Biosearch Life Company Information
- 8.4.2 Biosearch Life Business Overview
- 8.4.3 Biosearch Life Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Biosearch Life Alternative to Antibiotics Product Portfolio
- 8.4.5 Biosearch Life Recent Developments
- 8.5 China-Biotics
- 8.5.1 China-Biotics Company Information
- 8.5.2 China-Biotics Business Overview
- 8.5.3 China-Biotics Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 China-Biotics Alternative to Antibiotics Product Portfolio
- 8.5.5 China-Biotics Recent Developments
- 8.6 Chr. Hansen
- 8.6.1 Chr. Hansen Company Information
- 8.6.2 Chr. Hansen Business Overview
- 8.6.3 Chr. Hansen Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Chr. Hansen Alternative to Antibiotics Product Portfolio
- 8.6.5 Chr. Hansen Recent Developments
- 8.7 Danone
- 8.7.1 Danone Company Information
- 8.7.2 Danone Business Overview
- 8.7.3 Danone Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Danone Alternative to Antibiotics Product Portfolio
- 8.7.5 Danone Recent Developments
- 8.8 DuPont(Danisco)
- 8.8.1 DuPont(Danisco) Company Information
- 8.8.2 DuPont(Danisco) Business Overview
- 8.8.3 DuPont(Danisco) Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 DuPont(Danisco) Alternative to Antibiotics Product Portfolio
- 8.8.5 DuPont(Danisco) Recent Developments
- 8.9 Ganeden
- 8.9.1 Ganeden Company Information
- 8.9.2 Ganeden Business Overview
- 8.9.3 Ganeden Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Ganeden Alternative to Antibiotics Product Portfolio
- 8.9.5 Ganeden Recent Developments
- 8.10 Glory Biotech
- 8.10.1 Glory Biotech Company Information
- 8.10.2 Glory Biotech Business Overview
- 8.10.3 Glory Biotech Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Glory Biotech Alternative to Antibiotics Product Portfolio
- 8.10.5 Glory Biotech Recent Developments
- 8.11 Greentech
- 8.11.1 Greentech Company Information
- 8.11.2 Greentech Business Overview
- 8.11.3 Greentech Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Greentech Alternative to Antibiotics Product Portfolio
- 8.11.5 Greentech Recent Developments
- 8.12 Lallemand
- 8.12.1 Lallemand Company Information
- 8.12.2 Lallemand Business Overview
- 8.12.3 Lallemand Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Lallemand Alternative to Antibiotics Product Portfolio
- 8.12.5 Lallemand Recent Developments
- 8.13 Morinaga Milk Industry
- 8.13.1 Morinaga Milk Industry Company Information
- 8.13.2 Morinaga Milk Industry Business Overview
- 8.13.3 Morinaga Milk Industry Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Morinaga Milk Industry Alternative to Antibiotics Product Portfolio
- 8.13.5 Morinaga Milk Industry Recent Developments
- 8.14 Novozymes
- 8.14.1 Novozymes Company Information
- 8.14.2 Novozymes Business Overview
- 8.14.3 Novozymes Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Novozymes Alternative to Antibiotics Product Portfolio
- 8.14.5 Novozymes Recent Developments
- 8.15 Probi
- 8.15.1 Probi Company Information
- 8.15.2 Probi Business Overview
- 8.15.3 Probi Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Probi Alternative to Antibiotics Product Portfolio
- 8.15.5 Probi Recent Developments
- 8.16 Sabinsa
- 8.16.1 Sabinsa Company Information
- 8.16.2 Sabinsa Business Overview
- 8.16.3 Sabinsa Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Sabinsa Alternative to Antibiotics Product Portfolio
- 8.16.5 Sabinsa Recent Developments
- 8.17 Synbiotech
- 8.17.1 Synbiotech Company Information
- 8.17.2 Synbiotech Business Overview
- 8.17.3 Synbiotech Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Synbiotech Alternative to Antibiotics Product Portfolio
- 8.17.5 Synbiotech Recent Developments
- 8.18 UAS Laboratories
- 8.18.1 UAS Laboratories Company Information
- 8.18.2 UAS Laboratories Business Overview
- 8.18.3 UAS Laboratories Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 UAS Laboratories Alternative to Antibiotics Product Portfolio
- 8.18.5 UAS Laboratories Recent Developments
- 8.19 Valio
- 8.19.1 Valio Company Information
- 8.19.2 Valio Business Overview
- 8.19.3 Valio Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Valio Alternative to Antibiotics Product Portfolio
- 8.19.5 Valio Recent Developments
- 8.20 Yakult
- 8.20.1 Yakult Company Information
- 8.20.2 Yakult Business Overview
- 8.20.3 Yakult Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.20.4 Yakult Alternative to Antibiotics Product Portfolio
- 8.20.5 Yakult Recent Developments
- 8.21 Nestle
- 8.21.1 Nestle Company Information
- 8.21.2 Nestle Business Overview
- 8.21.3 Nestle Alternative to Antibiotics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.21.4 Nestle Alternative to Antibiotics Product Portfolio
- 8.21.5 Nestle Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Alternative to Antibiotics Value Chain Analysis
- 9.1.1 Alternative to Antibiotics Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Alternative to Antibiotics Production Mode & Process
- 9.2 Alternative to Antibiotics Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Alternative to Antibiotics Distributors
- 9.2.3 Alternative to Antibiotics Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst